1. Safety and efficacy of transarterial embolization of hepatocellular adenomas
- Author
-
van Rosmalen, B.V. (B. V.), Klompenhouwer, A.J. (Anne Julia), de Graeff, J.J. (J. Jaap), Haring, M.P.D. (M. P.D.), Meijer, V.E. (Vincent) de, Rifai, L. (L.), Dokmak, S. (S.), Rawashdeh, A. (A.), Abu Hilal, M., de Jong, M.C. (M. C.), Dejong, C.H.C. (C. H.C.), Doukas, M. (Michael), Man, R.A. (Robert) de, IJzermans, J.N.M. (Jan), Delden, O.M. (Otto) van, Verheij, J. (Joanne), Gulik, T.M. (Thomas) van, van Rosmalen, B.V. (B. V.), Klompenhouwer, A.J. (Anne Julia), de Graeff, J.J. (J. Jaap), Haring, M.P.D. (M. P.D.), Meijer, V.E. (Vincent) de, Rifai, L. (L.), Dokmak, S. (S.), Rawashdeh, A. (A.), Abu Hilal, M., de Jong, M.C. (M. C.), Dejong, C.H.C. (C. H.C.), Doukas, M. (Michael), Man, R.A. (Robert) de, IJzermans, J.N.M. (Jan), Delden, O.M. (Otto) van, Verheij, J. (Joanne), and Gulik, T.M. (Thomas) van
- Abstract
Background: Hepatocellular adenoma (HCA) larger than 5 cm in diameter has an increased risk of haemorrhage and malignant transformation, and is considered an indication for resection. As an alternative to resection, transarterial embolization (TAE) may play a role in prevention of complications of HCA, but its safety and efficacy are largely unknown. The aim of this study was to assess outcomes and postembolization effects of selective TAE in the management of HCA. Methods: This retrospective, multicentre cohort study included patients aged at least 18 years, diagnosed with HCA and treated with TAE. Patient characteristics, 30-day complications, tumour size before and after TAE, symptoms before and after TAE, and need for secondary interventions were analysed. Results: Overall, 59 patients with a median age of 33.5 years were included from six centres; 57 of the 59 patients were women. Median tumour size at time of TAE was 76 mm. Six of 59 patients (10 per cent) had a major complication (cyst formation or sepsis)
- Published
- 2019
- Full Text
- View/download PDF